(
(
Healthcare
Healthcare
)
)
Novel topical treatments for ophthalmic diseases
Novel topical treatments for ophthalmic diseases
Novel topical treatments for ophthalmic diseases
STATUS:
Current
Oculis is a global biopharmaceutical company dedicated to improving eye care and preserving sight. Their clinical-stage pipeline includes innovative product candidates for eye diseases with high unmet needs. Oculis aims to provide life-changing eye treatment worldwide.
Oculis is a global biopharmaceutical company dedicated to improving eye care and preserving sight. Their clinical-stage pipeline includes innovative product candidates for eye diseases with high unmet needs. Oculis aims to provide life-changing eye treatment worldwide.
(Entrepreneurs)
(Entrepreneurs)
Riad Sherif, CEO
Rebecca Weil, CCO
Sylvia Cheung, CFO
(VI Partners)
(VI Partners)
(Fund)
(Fund)
Vi-21
Portfolio News


OCT 06, 2025
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
Read More
Read more


OCT 06, 2025
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
Read More
Read more


AUG 01, 2025
Oculis Upsized Loan Facility to Access up to CHF 100 million
Read More
Read more


AUG 01, 2025
Oculis Upsized Loan Facility to Access up to CHF 100 million
Read More
Read more


FEB 14, 2025
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
Read More
Read more


FEB 14, 2025
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
Read More
Read more


